Tobradex St (Tobramycin/Dexamethasone) Patent Expiration, LOE Window & CMS Spending

Tobradex St (Tobramycin/Dexamethasone) by Harrow Eye: FDA Orange Book LOE 2028-08-03, 2 AB generics, $6.6M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorHarrow Eye
FDA Application & PathwayN050818 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2028-08-03
Orange Book Patents (*PED Extensions)3 patents (0 *PED)
Active AB-Rated Generic Competitors2
2024 CMS Total Public Spend$6.6M
2024 Medicare Part D Spend$6.0M
2024 Medicaid Spend$624K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel